March was an interesting month for the Aspect Large Cap Value fund.
I actually didn’t make any new trades, but there may be some potential M&A developments regarding certain stocks within the portfolio.
Continue Reading Below
Mylan could be a good fit for Teva in my view and a tie-up would help Teva defend its valuable Copaxone franchise.
A deal would also be beneficial to Teva’s efforts to build out its product pipeline.
Teva still sells at a low multiple as of the date of this report – most notably in comparison to Mylan.
Intel has been building a huge amount of capacity while smaller semiconductor companies have been going fabless. Intel does manufacture for Altera and is familiar with the company.
I am still bullish on Intel long term because I believe that their design and manufacturing processes remain unmatched.
Wait and See
On the non-merger front, the adult entertainment chain RCI International (RICK) remains a wait and see situation for me.
My investment thesis is that the company will launch a real estate investment trust of its property holdings and settle a tax lawsuit.
That hasn’t happened yet. It is frustrating to see the stock just sitting there – while fundamentally the company is doing very well, the stock has not moved.
This means that based on a $4 per share earnings estimate, the stock could go as high as $100 per share and still be considered reasonably priced, according to my research.
While I am not quite that bullish, I am letting time, not price dictate when I sell this stock. My tentative plan is to hold until late this year.
Finally, my metals and oil investments are aggravating but I believe that there is a lot of potential in these shares.
I am not really betting on an end to the bull market, but rather an increase in investor anxiety.
With the portfolio growing and the cash position still large but shrinking in relative size, I am leaning more toward selling than buying.
That said, at this point, I believe stocks in general seem to expensive to buy, and my value picks seem to cheap to sell for the most part.
In a market of stocks, I did nothing this month and reaped the rewards,
On a final note, although I do not invest in marijuana related stocks for this fund, I do believe that these stocks are putting in some sort of bottom.
While it is true that most of these stocks do not have real fundamentals to support their valuations, there are certain companies that are making progress.
Subscribe to our once-weekly email newsletter and get the best posts delivered to you in one convenient place, to browse at your leisure:
The investments discussed are held in client accounts as of April 2, 2015. These investments may or may not be currently held in client accounts. The reader should not assume that any investments identified were or will be profitable or that any investment recommendations or investment decisions we make in the future will be profitable.
The post Intel and Teva are on the prowl for deals appeared first on Smarter InvestingCovestor Ltd. is a registered investment advisor. Covestor licenses investment strategies from its Model Managers to establish investment models. The commentary here is provided as general and impersonal information and should not be construed as recommendations or advice. Information from Model Managers and third-party sources deemed to be reliable but not guaranteed. Past performance is no guarantee of future results. Transaction histories for Covestor models available upon request. Additional important disclosures available at http://site.covestor.com/help/disclosures.
Continue Reading Below